Matthew Olson Principle Research Scientist at Johnson & Johnson to Speak at GTCbio’s 3rd Assay Development & Screening Technologies Conference on June 5-6
Monrovia, CA, April 18, 2008 --(PR.com)-- Dr. Matthew Olson, Principle Research Scientist at Johnson & Johnson will give a presentation at GTCbio’s 3rd Assay Development & Screening Technologies Conference on June 5-6, 2008 in San Francisco, CA. Dr. Olsen will present on “Coupling Label-free and Flouormetric Functional Assays with Biophysical Binding Assays: A Comparison of Positives from an HTS Campaign.”
HTS campaigns continue to push assay limits. As a consequence, the use of labeled substrates and secondary detection methods that minimize interference issues are often employed. However, fluorescent labeling of a particular substrate can often result in the generation of a substrate that no longer resembles the physiological target. In addition, secondary detection techniques often result in an assay where initial velocity requirements are lost. To employ label-free systems, experimenters have had to face the reality of using of substrates that amplify interference issues and use substrate concentrations well above the KM-value (negating initial velocity conditions). The coupling of high-throughput mass spectroscopy (HTMS) in a functional assay eliminates the issues of using fluorgenic substrates and may allow the functional assay to more closely reflect the in vivo condition. The sensitivity of HTMS assays (when utilizing single ion monitoring) rivals optically based functional assays eliminating optical interference. HTMS assays eliminate complications from coupling enzymes, secondary detection methods, and allows for the examination of bifuctional enzyme reactions independently. In the present study, functional assays are coupled with a label-free biophysical binding assay (ThermofluorTM) giving an additional means of evaluating compound activity. The overlap between these orthogonal in vitro technologies enables rapid lead generation, optimization and development.
GTCbio's 3rd Assay Development and Screening Technologies conference provides attendees with critical information to utilize in the discovery and development of assays, while keeping them informed about the latest screening technologies for both high-throughput screening and high-content screening. Topics being covered include cell based assays, high throughput screening, high content screening, in vitro assays and screening, novel assay and screening technologies, and target validation. For more information visit www.gtcbio.com.
About GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Their goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCbio (626) 256-6405, (626) 256-6460 fax, nina.tran@gtcbio.com
###
HTS campaigns continue to push assay limits. As a consequence, the use of labeled substrates and secondary detection methods that minimize interference issues are often employed. However, fluorescent labeling of a particular substrate can often result in the generation of a substrate that no longer resembles the physiological target. In addition, secondary detection techniques often result in an assay where initial velocity requirements are lost. To employ label-free systems, experimenters have had to face the reality of using of substrates that amplify interference issues and use substrate concentrations well above the KM-value (negating initial velocity conditions). The coupling of high-throughput mass spectroscopy (HTMS) in a functional assay eliminates the issues of using fluorgenic substrates and may allow the functional assay to more closely reflect the in vivo condition. The sensitivity of HTMS assays (when utilizing single ion monitoring) rivals optically based functional assays eliminating optical interference. HTMS assays eliminate complications from coupling enzymes, secondary detection methods, and allows for the examination of bifuctional enzyme reactions independently. In the present study, functional assays are coupled with a label-free biophysical binding assay (ThermofluorTM) giving an additional means of evaluating compound activity. The overlap between these orthogonal in vitro technologies enables rapid lead generation, optimization and development.
GTCbio's 3rd Assay Development and Screening Technologies conference provides attendees with critical information to utilize in the discovery and development of assays, while keeping them informed about the latest screening technologies for both high-throughput screening and high-content screening. Topics being covered include cell based assays, high throughput screening, high content screening, in vitro assays and screening, novel assay and screening technologies, and target validation. For more information visit www.gtcbio.com.
About GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Their goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCbio (626) 256-6405, (626) 256-6460 fax, nina.tran@gtcbio.com
###
Contact
GTCbio
Nina Tran
626-256-6405
http://www.gtcbio.com
Nina Tran
626-256-6405
http://www.gtcbio.com
Contact
Categories